ARQT vs MRK · rev $235.3M vs P/E 33, rev $16.61B
Arcutis Biotherapeutics Inc (ARQT) versus Merck & Company Inc (MRK) — a side-by-side from cached financials, not a winner call.
Arcutis Biotherapeutics Inc (ARQT) is a biotechnology company listed on US.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Rob Davis.
Latest reported ARQT revenue for 2026-06-30 was $235.3M. Net income was $3.7M. ARQT currently screens at market cap $1.64B.
Latest reported MRK revenue for 2026-06-30 was $16.61B. Net income was -$1.33B. Revenue was up 2.0% from 2026-03-31 to 2026-06-30. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
ARQT currently screens at market cap $1.64B. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Not investment advice. Open the ARQT and MRK stock pages for the full models.
Not investment advice.